Trial · NCT03052608
Results by group576
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 576
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment | Lorlatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment | Crizotinib | 9.3 | 95% Confidence Interval 7.6 to 11.1 | Months | |
| Overall Survival (OS) | Lorlatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) | Crizotinib | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-Free Survival (PFS) Based on Investigator's Assessment | Lorlatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-Free Survival (PFS) Based on Investigator's Assessment | Crizotinib | 9.1 | 95% Confidence Interval 7.4 to 10.9 | Months | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment | Lorlatinib | 75.8 | 95% Confidence Interval 68.2 to 82.5 | Percentage of participants | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment | Crizotinib | 57.8 | 95% Confidence Interval 49.4 to 65.9 | Percentage of participants | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment | Lorlatinib | 80.5 | 95% Confidence Interval 73.3 to 86.6 | Percentage of participants | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment | Crizotinib | 61.9 | 95% Confidence Interval 53.5 to 69.8 | Percentage of participants | |
| Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment | Lorlatinib | 65.8 | 95% Confidence Interval 48.6 to 80.4 | Percentage of participants | |
| Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment | Crizotinib | 20.0 | 95% Confidence Interval 9.1 to 35.6 | Percentage of participants | |
| Intracranial Time to Progression (IC-TTP) Based on BICR Assessment | Lorlatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Intracranial Time to Progression (IC-TTP) Based on BICR Assessment | Crizotinib | 16.6 | 95% Confidence Interval 11.1 to NA | Months | |
| Duration of Response (DR) Based on BICR Assessment | Lorlatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Duration of Response (DR) Based on BICR Assessment | Crizotinib | 11.0 | 95% Confidence Interval 9.0 to 12.9 | Months | |
| Intracranial Duration of Response (IC-DR) Based on BICR Assessment | Lorlatinib | NA | 95% Confidence Interval NA to NA | Months | |
| Intracranial Duration of Response (IC-DR) Based on BICR Assessment | Crizotinib | 9.4 | 95% Confidence Interval 6.0 to 11.1 | Months | |
| Time to Tumor Response (TTR) Based on BICR Assessment | Lorlatinib | 1.8 | Inter-Quartile Range 1.7 to 1.9 | Months | |
| Time to Tumor Response (TTR) Based on BICR Assessment | Crizotinib | 1.8 | Inter-Quartile Range 1.7 to 1.9 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03052608/results